US › Healthcare

Lucid Diagnostics Inc (LUCD)

US · Healthcare · Medical Devices

$0.40+2.03%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$1.5M

Revenue YoY

+26.7%

Net profit

$-11.7M

EPS

$-0.08

EPS estimate

$-0.05

Net margin

-792.9%

EPS came in at -0.08 against a street estimate of -0.05 — a miss of 60.0%.

Key statistics

Market cap

$74.5M

Forward P/E

0.0

P/B

7.29

Book value

$0.06

EPS (TTM)

$-0.44

52-week high

$1.63

52-week low

$0.30

50-day MA

$0.68

200-day MA

$1.01

Beta

1.16

Analyst view

Analysts rate Lucid Diagnostics Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $4.00.

Shareholding

Insiders

26.50%

Institutions

32.71%

Largest institutional holders

Fund	Stake
Alyeska Investment Group, L.P.	4.64%
BlackRock Inc	4.38%
Vanguard Capital Management, LLC	3.43%
Masters Capital Management LLC	2.09%
Aberdeen Group PLC	2.00%
Geode Capital Management, LLC	1.98%
State Street Corp	1.28%
First Manhattan Co. LLC	1.15%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lucid Diagnostics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.